# Everlaan Organics Inc · 66-41 · CANADA — FDA import alert red lists: firms subject to detention without physical examination

For Everlaan Organics Inc · 66-41 · CANADA, import alert is 66-41; import alert name is Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S; country is CANADA; product is Joint Pain Relief | Muscle Pain Relief | Muscle Pain Relief | Joint Pain Relief | Muscle Pain Relief | Joint Pain Relief; product code is 62 G - - 99 Anti-Inflammatory N.E.C. | 62 G - - 99 Anti-Inflammatory N.E.C. | 62 U - - 99 Anti-Tussive/Cold N.E.C. | 62 U - - 99 Anti-Tussive/Cold N.E.C. | 66 V - - 99 Miscellaneous Patent Medicines, Etc. | 66 V - - 99 Miscellaneous Patent Medicines, Etc; date published is 06/30/2025; address is 17220 Heather Dr Unit 106 , Surrey, British Columbia CANADA, verified against its source on 2026-09-16.

- **Firm:** Everlaan Organics Inc _(verified: appears in the quote below)_
- **Import alert:** 66-41
- **Import alert name:** Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.
- **Country:** CANADA _(verified: appears in the quote below)_
- **Address:** 17220 Heather Dr Unit 106 , Surrey, British Columbia CANADA _(verified: appears in the quote below)_
- **Date published:** 06/30/2025 _(verified: appears in the quote below)_
- **Product code:** 62 G - - 99 Anti-Inflammatory N.E.C. | 62 G - - 99 Anti-Inflammatory N.E.C. | 62 U - - 99 Anti-Tussive/Cold N.E.C. | 62 U - - 99 Anti-Tussive/Cold N.E.C. | 66 V - - 99 Miscellaneous Patent Medicines, Etc. | 66 V - - 99 Miscellaneous Patent Medicines, Etc. _(verified: each item appears in the quote below)_
- **Product:** Joint Pain Relief | Muscle Pain Relief | Muscle Pain Relief | Joint Pain Relief | Muscle Pain Relief | Joint Pain Relief _(verified: each item appears in the quote below)_
- **FDA notes:** Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. _(verified: each item appears in the quote below)_

## What the source says

> Everlaan Organics Inc Date Published : 06/30/2025 17220 Heather Dr Unit 106 , Surrey, British Columbia CANADA 62 G - - 99 Anti-Inflammatory N.E.C. Date Published: 06/30/2025 Desc: Joint Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 62 G - - 99 Anti-Inflammatory N.E.C. Date Published: 06/30/2025 Desc: Muscle Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 62 U - - 99 Anti-Tussive/Cold N.E.C. Date Published: 06/30/2025 Desc: Muscle Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 62 U - - 99 Anti-Tussive/Cold N.E.C. Date Published: 06/30/2025 Desc: Joint Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 06/30/2025 Desc: Muscle Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 06/30/2025 Desc: Joint Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)].

## Source

- https://www.accessdata.fda.gov/cms_ia/importalert_190.html

Last verified: 2026-09-16. Review by: 2026-11-15.
Part of [FDA import alert red lists: firms subject to detention without physical examination](https://referencesource.org/fda-import-alert-red-list/).